What Is Microdosing?
Understanding sub-perceptual dosing, how psilocybin works in the brain, and what the research shows
The Core Idea
Microdosing is the practice of taking a sub-perceptual dose of a psychedelic substance — typically 1/10th to 1/20th of a full "trip" dose. The goal is not to feel high or experience hallucinations. Instead, the dose should be subtle enough that you can go about your normal day — work, socialize, exercise — while experiencing gentle improvements in mood, creativity, focus, or emotional openness.
Why People Microdose
- Mental health — Reduced symptoms of depression, anxiety, PTSD, and emotional numbness
- Cognitive enhancement — Improved focus, creativity, problem-solving, and mental clarity
- Emotional well-being — Greater self-awareness, empathy, emotional regulation, and mindfulness
- Habit change — Help breaking addictive patterns (smoking, alcohol, unhealthy behaviors)
- Neuroplasticity — Encouraging the brain to form new connections and break out of rigid patterns
What Microdosing Is NOT
- It is not a trip or a high
- It is not a daily supplement — tolerance builds quickly
- It is not a magic pill — it works best combined with intentional practices (journaling, meditation, exercise)
- It is not one-size-fits-all — dose must be calibrated to your body, sensitivity, and truffle variety
How Psilocybin Works in the Brain
Psilocybin is a prodrug — once ingested, your body converts it into psilocin, the active compound. Psilocin primarily activates serotonin 5-HT2A receptors, which are concentrated in the cerebral cortex.
Serotonin System
Psilocin binds to 5-HT2A serotonin receptors, the same system targeted by antidepressants (SSRIs), but through a fundamentally different mechanism. Rather than increasing serotonin availability, psilocin directly stimulates receptors that modulate mood, cognition, and perception.
Default Mode Network (DMN)
The DMN is the brain network responsible for self-referential thinking — your inner monologue, rumination, ego, and sense of self. In depression and anxiety, the DMN becomes hyperactive, creating endless rumination loops. Psilocybin reduces DMN activity, which:
- Quiets the "inner critic" and repetitive negative thought patterns
- Enhances connectivity between brain regions that don't normally communicate
- Creates a more flexible, less rigid mental state
Neuroplasticity
Psilocybin promotes the growth of new dendritic spines (connections between neurons) in the frontal cortex by activating 5-HT2A receptors, which triggers glutamate release, increases BDNF (Brain-Derived Neurotrophic Factor), and stimulates long-term potentiation. This means psilocybin doesn't just change how you feel in the moment — it may physically rewire neural circuits over time.
| Microdose | Full Dose | |
|---|---|---|
| Perception | Sub-perceptual — no hallucinations | Significant perceptual changes |
| DMN Effect | Mild reduction in rigidity | Significant disruption, possible ego dissolution |
| Neuroplasticity | Gradual changes over weeks | Rapid, intense neuroplastic window |
| Function | Normal daily activity | Cannot function normally for 4-6 hours |
| Serotonin | Subtle enhancement of signaling | Intense receptor activation |
| Duration | 3-5 hours (subtle) | 4-8 hours (intense) |
Reported Benefits
Surveys, community analysis, and clinical observation have documented a range of reported benefits. Note that most microdosing evidence is observational and self-reported — rigorous placebo-controlled trials are limited but growing.
Mental Health
- Reduced symptoms of depression and anxiety
- Improved emotional regulation
- Less rumination and negative thinking
- Greater emotional openness
Cognitive
- Enhanced focus and concentration
- Increased creativity (12.9% of users)
- Improved problem-solving
- Greater mental clarity
Social
- Improved social interactions
- Better mood and positive outlook (26.6%)
- Healthier habits and routines
- Reduced substance dependence
Physical
- Increased energy without jitters
- Enhanced sensory awareness
- Possible migraine reduction
- Better mind-body connection
Key Studies
- Imperial College London — Demonstrated psilocybin therapy can match SSRIs for major depression; fMRI studies show enhanced brain connectivity even at sub-hallucinogenic doses
- Johns Hopkins University — 80% smoking cessation success rate at 6-month follow-up; sustained decreases in depression and anxiety in cancer patients
- Scientific Reports (2022) — Large observational study (n=953): microdosers showed greater improvements in mood and mental health at one month vs. controls
- Psychopharmacology (2019) — Most common benefits: improved mood (26.6%), focus (14.8%), creativity (12.9%). Most common side effects: physiological discomfort (18%), increased anxiety (6.7%)
Next: Learn About Truffles
Understand what psilocybin truffles are, why they're legal in the Netherlands, and which varieties are best for microdosing.
Truffle Varieties & Potency